Literature DB >> 19306815

Transplantation for cholangiocarcinoma: when and for whom?

David J Rea1, Charles B Rosen, David M Nagorney, Julie K Heimbach, Gregory J Gores.   

Abstract

Liver transplantation for cholangiocarcinoma has historically been maligned. Because of a high recurrence rate and poor patient survival, the disease has been viewed as an absolute contraindication to transplantation. Based on good results using neoadjuvant and palliative radiation, a protocol for liver transplantation in selected patients with unresectable hilar cholangiocarcinoma was developed in 1993. Neoadjuvant radiation is followed by operative staging to rule out patients with lymph node metastases before liver transplantation. This approach has achieved results superior to standard surgical therapy, with 72% 5-year survival for patients with unresectable disease.

Entities:  

Mesh:

Year:  2009        PMID: 19306815     DOI: 10.1016/j.soc.2008.12.008

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  24 in total

Review 1.  Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer.

Authors:  J R A Skipworth; S W M Olde Damink; C Imber; J Bridgewater; S P Pereira; M Malagó
Journal:  Aliment Pharmacol Ther       Date:  2011-09-20       Impact factor: 8.171

2.  Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis.

Authors:  John R Bergquist; Tommy Ivanics; Curtis B Storlie; Ryan T Groeschl; May C Tee; Elizabeth B Habermann; Rory L Smoot; Michael L Kendrick; Michael B Farnell; Lewis R Roberts; Gregory J Gores; David M Nagorney; Mark J Truty
Journal:  J Surg Oncol       Date:  2016-07-20       Impact factor: 3.454

Review 3.  Cholangiocarcinoma--controversies and challenges.

Authors:  Tushar Patel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04       Impact factor: 46.802

Review 4.  Pathology of Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma.

Authors:  Murli Krishna
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-05-01

Review 5.  Recent advances in the regulation of cholangiocarcinoma growth.

Authors:  Heather Francis; Gianfranco Alpini; Sharon DeMorrow
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-04-29       Impact factor: 4.052

Review 6.  Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making.

Authors:  Irinel Popescu; Traian Dumitrascu
Journal:  Langenbecks Arch Surg       Date:  2014-05-20       Impact factor: 3.445

Review 7.  The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma.

Authors:  Massimiliano Cadamuro; Tommaso Stecca; Simone Brivio; Valeria Mariotti; Romina Fiorotto; Carlo Spirli; Mario Strazzabosco; Luca Fabris
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-07-27       Impact factor: 5.187

Review 8.  Preneoplastic conditions underlying bile duct cancer.

Authors:  Lena Sibulesky; Justin Nguyen; Tushar Patel
Journal:  Langenbecks Arch Surg       Date:  2012-03-06       Impact factor: 3.445

9.  Primary Sclerosing Cholangitis: Current and Future Management Strategies.

Authors:  John E Eaton; Jayant A Talwalkar
Journal:  Curr Hepat Rep       Date:  2013-03-01

Review 10.  Update on the management of cholangiocarcinoma.

Authors:  J R A Skipworth; M G Keane; S P Pereira
Journal:  Dig Dis       Date:  2014-07-14       Impact factor: 2.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.